Brewin Dolphin LTD Uni Qure N.V. Transaction History

Brewin Dolphin LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Nov 14, 2022	SELL	$13.15 - $20.45 $9,731 - $15,133	-740 Closed	0 $0
Q1 2022 Nov 14, 2022	BUY	$14.54 - $21.5 $10,759 - $15,910	740 New	740 $13,000
Q1 2021 Nov 09, 2023	BUY	$29.24 - $42.03 $21,637 - $31,102	740 New	740 $24.9 Million
Q1 2018 Nov 09, 2023	SELL	$17.1 - $26.61 $80,370 - $125,067	-4,700 Closed	0 $0
Q3 2017 Nov 09, 2023	BUY	$7.7 - $9.6 $36,190 - $45,120	4,700	4,700 $45.1 Million

141

33.7M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $237M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Brewin Dolphin LTD, based on Form 13F filings with the SEC.

Stay updated on Brewin Dolphin LTD with notifications on news.